脾脏在慢性应激促肝癌进展中的作用

江 维1,李 宇2,韦 巍1,张淑群1,李宗芳1*

(1.西安交通大学第二附属医院肿瘤外科,生物诊断治疗国家地方联合工程研究中心,陕西 西安 710004;2.西安交通大学第二附属医院胸外科,陕西 西安 710004)

[摘要] 目的探讨脾脏在慢性应激促肝癌进展中的作用。方法建立H22肝癌细胞皮下种植瘤模型,通过慢性束缚应激模型探索慢性应激对肝癌进展的影响;通过流式细胞术检测外周血和肿瘤组织CD11b+Ly6C+CCR2+单核细胞的比例;通过脾切除考察脾脏在慢性应激促肝癌进展中的作用。结果应激组肿瘤重量明显高于对照组,外周血CD11b+Ly6C+CCR2+单核细胞的比例明显高于对照组,差异有统计学意义(P<0.05);对照组和应激组肿瘤组织中CD11b+Ly6C+CCR2+单核细胞的比例差异无统计学意义(P>0.05)。假手术应激组肿瘤重量明显高于假手术组和脾切除应激组,外周血CD11b+Ly6C+CCR2+单核细胞的比例明显高于假手术组和脾切除应激组,差异有统计学意义(P<0.01);假手术组和脾切除应激组肿瘤重量、外周血CD11b+Ly6C+CCR2+单核细胞的比例差异无统计学意义(P>0.05);假手术组、假手术应激组和脾切除应激组肿瘤组织中CD11b+Ly6C+CCR2+单核细胞的比例差异无统计学意义(P>0.05)。结论慢性应激促进肝癌进展并抑制抗肿瘤免疫,脾切除可能通过降低CD11b+Ly6C+CCR2+单核细胞比例而减缓慢性应激小鼠肝脏的进展。

[关键词] 肝肿瘤;脾;慢性应激 doi:10.3969/j.issn.1007-3205.2021.05.006

随着传统医学模型向生物-心理-社会医学模式逐渐转变,证实慢性应激与肿瘤的发生发展密切相关,给予肿瘤患者心理治疗、社会支持、针对慢性应激的药物治疗均可以改善患者的预后[1]。基础研究证实,慢性应激通过应激激素(肾上腺素、去甲肾上腺素、糖皮质激素等)促进肿瘤的发生发展,而免疫因素在慢性应激促肿瘤进展中具有重要作用[2-3]。高表达趋化因子受体2(chemokine receptor 2,CCR2)的单核细胞趋化至肿瘤组织将分化为肿瘤相关巨噬细胞(tumor-associated macrophages,TAM),而TAM通过多种途径促进肿瘤进展[4]。有文献报道慢性应激通过增加体内CCR2+单核细胞的比例进而促进肿瘤进展[5]。脾脏在肿瘤发生发展中具有重要作用。临床研究表明,外伤脾切除会增加肿瘤发生的风险,而切除病理脾脏(如门静脉高压症脾功能亢进的脾脏)能降低肝癌的发生风险[6-7]。脾脏是单核巨噬细胞的重要来源之一,同时也是肿瘤免疫耐受发生的部位,在肿瘤进展期切除脾脏可以减少肿瘤组织中单核巨噬细胞的数量,提高CD8+T细胞的细胞毒性,抑制肿瘤的生长[8-9]。由此可见,脾脏参与了肿瘤的进展,但脾脏在慢性应激促肿瘤进展中的作用尚不清楚。因此,本研究旨在探讨脾脏在慢性应激促肝癌进展中的作用。

1 材料与方法

1.1 实验动物 6~8周龄雄性C57BL/6小鼠28只,体重(20±2)g,为SPF级,购买于西安交通大学医学部实验动物中心,并饲养于西安交通大学医学部实验动物中心SPF标准动物房内。动物实验经西安交通大学医学部伦理委员会批准通过。

1.2 细胞株及细胞培养 H22细胞株购自中国典型培养物保藏中心。H22细胞培养于含有10%胎牛血清(购自Gibco)、1%青霉素-链霉素溶液(购自碧云天公司)的1640完全培养基中(购自Hyclone公司),在5%CO2、37 ℃饱和湿度的细胞培养箱中培养24 h后,用15 mL离心管收集起来,于1 000 r/min 常温离心5 min,弃掉上清,用生理盐水重悬,备用。

1.3 主要抗体 大鼠抗小鼠PE/Cyanine7-labeled CCR2、大鼠抗小鼠PE-labeled Ly6C、大鼠抗小鼠CD16/32、大鼠抗小鼠APC-labeled CD11b、大鼠抗小鼠Brilliant Violet 421TM-labeled CD45抗体购自美国Biolegend公司。

1.4 慢性束缚应激荷瘤小鼠模型的建立 待小鼠适应环境2周后,慢性应激小鼠给予束缚应激,2 h/d,应激方法是将小鼠水平束缚在通气的50 mL离心管中。应激5 d后皮下接种H22肝癌细胞建立皮下瘤模型。其具体方法为:将上述复苏并培养了24 h后的H22肝癌细胞用生理盐水重悬,并调整H22细胞浓度为1×107个/mL,吸取0.1 mL细胞悬液,无菌注射到小鼠腹腔内,等待小鼠出现大量腹腔积液后,无菌取出小鼠腹腔积液至15 mL离心管中,用生理盐水洗涤2次,每次洗后1 000 r/min离心5 min,去上清,用12 mL生理盐水重悬细胞,并将H22肝癌细胞稀释至5×106个/mL。用1 mL注射器小鼠左侧腹股沟处30度角度缓慢刺入皮下,并斜行进针1 cm左右后注入100 μL H22细胞悬液,见注射部位出现小皮丘,无漏液,证明注射成功。缓慢拔出注射器,用棉签轻压进针口1 min左右。接种肿瘤后继续应激21 d。

1.5 脾切除及假手术 为了排除手术的影响,于慢性应激前2周行脾切除或假手术,在紫外线灭菌后的环境下,腹腔注射4%水合氯醛(0.01 mL/g体重)麻醉小鼠,备皮并用碘伏消毒3遍,取腹部正中切口长约0.8 cm,充分暴露脾脏,分别用缝合线结扎脾脏上极和下极的血管后剪掉血管,最后将脾脏游离下来并摘除。检测血管结扎处是否有出血后,逐层缝合腹腔,碘伏消毒皮层后将小鼠侧卧保温复苏。假手术仅打开腹腔,不做脾切除术,直接缝合腹腔。

1.6 外周血及肿瘤单细胞悬液制备 小鼠接种肿瘤3周后用眼球取血法采血约1.0 mL于乙二胺四乙酸抗凝管中备用,并取其肿瘤组织称重。将上述所取乙二胺四乙酸抗凝血加入5 mL红细胞裂解液充分混匀,冰上孵育5 min,用含2 %胎牛血清的PBS 10 mL终止,4 ℃下350 g离心5 min,取沉淀细胞并用1 mL PBS重悬,计数,调细胞浓度为1×107~2×107个/mL,放置于冰上,备用。将获取的肿瘤组织用眼科剪剪碎,并加入DNaseⅠ(购自上海生工生物)和Ⅳ型胶原酶(购自上海生工生物),使其终浓度分别为1.5 g/L和3 g/L,于37 ℃下孵育30 min,并用200目尼龙网过滤,以获得单个细胞,4 ℃下350 g离心5 min,弃去上清液取沉淀细胞;用1 mL PBS重悬,计数,调细胞浓度为1×107~2×107个/mL,放置于冰上,备用。

1.7 流式细胞术检测肿瘤和外周血CD11b+Ly6C+CCR2+单核细胞的比例 吸取100 μL上述制备的细胞悬液加入流式管中,用抗大鼠抗小鼠CD16/32抗体4 ℃孵育15 min,按说明书加入适量的CCR2、Ly6C、CD11b、CD45抗体,4 ℃避光孵育30 min,后加入含1%胎牛血清的PBS 2 mL,4 ℃下350 g离心5 min,弃去上清液;重复1次,最后加入0.5 mL PBS重悬,用FACS Canto Ⅱ flow cytometer(美国BD公司)检测结果。

1.8 统计学方法 应用SPSS 13.0统计学软件分析数据。计量资料比较采用t检验、单因素方差分析和SNK-q检验。P<0.05为差异有统计学意义。

2 结 果

2.1 慢性应激对肝癌进展的影响 采取接种肿瘤前连续束缚应激5 d,接种肿瘤后再连续束缚应激21 d的慢性应激模型探讨慢性应激对肝癌进展的影响(图1),结果显示,对照组肿瘤重量为(0.109±0.040) g,应激组肿瘤重量为(0.283±0.047) g,应激组肿瘤重量明显大于对照组,差异有统计学意义(t=2.810,P=0.023)。

图1 慢性应激对肝癌进展的影响

Figure 1 The impact of chronic stress on hepatic carcinoma progression

2.2 慢性应激对CD11b+Ly6C+CCR2+单核细胞的影响 因CD11b+Ly6C+CCR2+单核细胞能促进肿瘤的进展,进一步用流式细胞术检测慢性应激对荷瘤小鼠外周血和肿瘤组织CD11b+Ly6C+CCR2+单核细胞比例的影响。结果显示,应激组外周血CD11b+Ly6C+CCR2+单核细胞的比例明显高于对照组,差异有统计学意义(P<0.05,图2);对照组和应激组肿瘤组织CD11b+Ly6C+CCR2+单核细胞的比例差异无统计学意义(P>0.05)。见表1。

图2 慢性应激对外周血CD11b+Ly6C+CCR2+单核细胞的影响

A.对照组外周血CD11b+Ly6C+CCR2+单核细胞代表性流式图;B.应激组外周血CD11b+Ly6C+CCR2+单核细胞代表性流式图

Figure 2 The impact of chronic stress on the proportion of CD11b+Ly6C+CCR2+ monocyte in peripheral blood

表1 慢性应激对荷瘤小鼠外周血和肿瘤组织
CD11b+Ly6C+CCR2+单核细胞的影响
Table 1 The impact of chronic stress on the proportion of
CD11b+Ly6C+CCR2+ monocyte in the peripheral blood
and tumor tissue of tumor-bearing mice

组别CD11b+Ly6C+CCR2+单核细胞比例外周血肿瘤组织应激组11.35±0.781.83±0.10对照组7.08±1.351.64 ±0.27t值2.7400.654P值0.0250.542

2.3 脾脏在慢性应激促肝癌进展中的作用 用脾切除的手段探讨脾脏在慢性应激促肝癌进展中的作用。结果显示,假手术应激组肿瘤重量明显高于假手术组和脾切除应激组,差异有统计学意义(P<0.05), 假手术组和脾切除应激组肿瘤重量差异无统计学意义(P>0.05)。见表2。

表2 脾脏在慢性应激促肝癌进展中的作用
Table 2 The role of the spleen in progression of hepatic
carcinoma induced by chronic stress

组别肿瘤重量假手术组 0.120±0.030 假手术应激组0.376±0.052*脾切除应激组0.205±0.037#F值10.303P值0.002

*P值<0.05与假手术组比较 #P值<0.05与假手术应激组比较(SNK-q检验)

2.4 脾切除对慢性应激荷瘤小鼠CD11b+Ly6C+CCR2+单核细胞的影响 检测脾切除对慢性应激荷瘤小鼠外周血和肿瘤组织CD11b+Ly6C+CCR2+单核细胞比例的影响。结果显示,与假手术组(7.65±0.78)%相比,假手术应激组外周血CD11b+Ly6C+CCR2+单核细胞的比例明显高于假手术组和脾切除应激组,差异有统计学意义(P<0.05),假手术组和脾切除应激组外周血CD11b+Ly6C+CCR2+单核细胞的比例差异无统计学意义(P>0.05)。假手术组、假手术应激组和脾切除应激组肿瘤组织CD11b+Ly6C+CCR2+单核细胞的比例差异无统计学意义(P>0.05)。见表3。

表3 脾切除对慢性应激荷瘤小鼠
CD11b+Ly6C+CCR2+单核细胞的影响
Table 3 The impact of splenectomy on the proportion of
CD11b+Ly6C+CCR2+ monocyte in chronic
stressed tumor-bearing mice

组别 CD11b+Ly6C+CCR2+单核细胞比例外周血肿瘤组织假手术组 7.65±0.781.52±0.16假手术应激组11.71±0.79*1.86±0.15脾切除应激组8.12±1.01#1.73±0.11F值 6.6311.448P值 0.0090.266

*P值<0.05与假手术组比较 #P值<0.05与假手术应激组比较(SNK-q检验)

3 讨 论

研究证实,慢性应激能通过抑制肿瘤的免疫微环境促进肿瘤进展[10]。高表达CCR2的单核细胞是肿瘤免疫微环境的重要组成部分,其分化为TAM,而TAM通过多种途径促进肿瘤进展[4]。慢性应激通过增加体内CCR2+单核细胞的比例促进肿瘤进展。Armaiz-Pena等[3]研究表明,慢性束缚应激通过交感神经系统上调肿瘤细胞表达CCL2,进而趋化单核巨噬细胞到肿瘤组织促进肿瘤生长;Chen等[5]研究结果表明,慢性应激通过交感神经系统上调肺组织表达CCL2,从而通过CCL2-CCR2通路趋化单核巨噬细胞到转移灶,进而促进乳腺癌的肺转移。本研究证实,慢性束缚应激促进肝癌进展并增加外周血CD11b+Ly6C+CCR2+单核细胞的比例,由此可见,慢性应激可能通过增加CD11b+Ly6C+CCR2+单核细胞的比例促进肝癌进展,但其具体机制需要进一步研究。

脾脏是机体最大的外周免疫器官,也是重要的髓外造血部位,参与多种疾病的发生发展,比如肿瘤、肝炎肝硬化、心脑血管疾病等[11-14]。脾脏对肿瘤的作用还未有定论,有的研究表明切除脾脏能促进肿瘤进展[15-16],有的研究表明切除脾脏对肿瘤的生长没有影响[17-18]。前期研究结果显示,脾切除能够抑制肿瘤进展[19-20]。不同的实验结果可能是由不同的动物模型和不同的切脾时间造成的,其具体机制还有待进一步研究。最近研究结果显示,脾脏作为一个重要的髓外造血的器官,是单核巨噬细胞的重要来源之一,荷瘤小鼠脾脏显著增大,脾脏同时是肿瘤免疫耐受的发生部位[8,21]。切除脾脏能抑制肿瘤的生长和减少单核巨噬细胞的数量[8-9]。前期研究表明,肝纤维化模型大鼠较正常大鼠脾脏中CCR2+单核巨噬细胞数量显著增加,肝纤维化模型大鼠切脾后肝脏单核巨噬细胞数量降低,说明脾脏是CCR2+单核细胞的重要来源之一[22]。慢性应激能促进脾脏中的单核巨噬细胞分布到外周器官,而慢性应激能招募脾脏中的单核细胞到小鼠大脑[23-25]。本研究结果显示,在造模前14 d切除脾脏能减缓慢性应激诱导的肿瘤生长,也能显著减少慢性应激小鼠外周血CD11b+Ly6C+CCR2+单核细胞的比例。由此可见,脾脏在慢性应激促肿瘤进展过程中起促进作用,慢性应激增加外周血CD11b+Ly6C+CCR2+单核细胞可能来源于脾脏。

[参考文献]

[1] McGregor BA,Antoni MH. Psychological intervention and health outcomes among women treated for breast cancer:a review of stress pathways and biological mediators [J]. Brain Behav Immun,2009,23(2):159-166.

[2] Bucsek MJ,Qiao G,MacDonald CR,et al. beta-Adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8+ T cells and undermines checkpoint inhibitor therapy [J]. Cancer Res,2017,77(20):5639-5651.

[3] Armaiz-Pena GN,Gonzalez-Villasana V,Nagaraja AS,et al. Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth [J]. Oncotarget,2015,6(6):4266-4273.

[4] Qian B,Li J,Zhang H,et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis [J]. Nature,2011, 475(7355):222-225.

[5] Chen H,Liu D,Guo L,et al. Chronic psychological stress promotes lung metastatic colonization of circulating breast cancer cells by decorating a pre-metastatic niche through activating beta-adrenergic signaling [J]. J Pathol,2018,244(1):49-60.

[6] Kristinsson SY,Gridley G,Hoover RN,et al. Long-term risks after splenectomy among 8,149 cancer-free American veterans:a cohort study with up to 27 years follow-up[J]. Haematologica,2014,99(2):392-398.

[7] Lv X,Yang F,Guo X,et al. Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis[J]. Tumour Biol,2016,37(7):8889-8900.

[8] Cortez-Retamozo V,Etzrodt M,Newton A,et al. Origins of tumor-associated macrophages and neutrophils[J]. Proc Natl Acad Sci U S A,2012,109(7):2491-2496.

[9] Ugel S,Peranzoni E,Desantis G,et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen[J]. Cell Rep,2012,2(3):628-639.

[10] Jiang W,Li Y,Li ZZ,et al. Chronic restraint stress promotes hepatocellular carcinoma growth by mobilizing splenic myeloid cells through activating β-adrenergic signaling [J]. Brain Behav Immun,2019,80:825-838.

[11] Dragomir M,Petrescu DGE,Manga GE,et al. Patients after splenectomy:old risks and new perspectives[J]. Chirurgia(Bucur),2016,111(5):393-399.

[12] 李宗芳,周蕊,任松,等. 脾脏与肝病的研究进展[J]. 国际外科学杂志,2012,39(4):217-221.

[13] 张澍,李宗芳. 脾脏功能与脾脏外科研究现状与展望[J]. 中华实验外科杂志,2014,31(2):231-233.

[14] Li L,Duan M,Chen W,et al. The spleen in liver cirrhosis:revisiting an old enemy with novel targets [J]. J Transl Med,2017,15(1):111-121.

[15] Prehn RT. The paradoxical effects of splenectomy on tumor growth[J]. Theor Biol Med Model,2006,3:23.

[16] Higashijima J,Shimada M,Chikakiyo M,et al. Effect of splenectomy on antitumor immune system in mice[J]. Anticancer Res,2009,29(1):385-393.

[17] Soda K,Kawakami M,Takagi S,et al. Splenectomy before tumor inoculation prolongs the survival time of cachectic mice[J]. Cancer Immunol Immunother,1995,41(4):203-209.

[18] Imai S,Nio Y,Shiraishi T,et al. Effects of splenectomy on pulmonary metastasis and growth of SC42 carcinoma transplanted into mouse liver[J]. J Surg Oncol,1991,47(3):178-187.

[19] 李宝华,黄娜,陈海燕,等.肝癌小鼠脾脏免疫细胞的变化及其意义[J].现代肿瘤医学,2018,26(13):1980-1985.

[20] Li B,Zhang S,Huang N,et al. CCL9/CCR1 induces myeloid derived suppressor cell recruitment to the spleen in a murine H22 orthotopic hepatoma model[J]. Oncol Rep,2019,41(1):608-618.

[21] 程馥艳,刘锡文,徐晓武.三七总皂苷对人肝癌细胞HepG2移植瘤增殖的影响及其机制的研究[J].河北医科大学学报,2011,32(4):447-449.

[22] Li L,Wei W,Li Z,et al. The Spleen promotes the secretion of CCL2 and supports an M1 dominant phenotype in hepatic macrophages during liver fibrosis[J]. Cell Physiol Biochem,2018,51(2):557-574.

[23] Wohleb ES,McKim DB,Shea DT,et al. Re-establishment of anxiety in stress-sensitized mice is caused by monocyte trafficking from the spleen to the brain[J]. Biological Psychiatry,2014,75(12):970-981.

[24] McKim DB,Patterson JM,Wohleb ES,et al. Sympathetic release of splenic monocytes promotes recurring anxiety following repeated social defeat[J]. Biological Psychiatry,2016,79(10):803-813.

[25] Jiang W,Li Y,Sun J,et al. Spleen contributes to restraint stress induced changes in bloodleukocytes distribution[J]. Sci Rep,2017,7(1):6501.

The role of the spleen in progression of hepatic carcinoma induced by chronic stress

JIANG Wei1, LI Yu2, WEI Wei1, ZHANG Shu-qun1, LI Zong-fang1*

(1.Department of Oncology, National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, the Second Affiliated Hospital of Xian Jiaotong University, Xian 710004, China; 2.Department of Thoracic Surgery, the Second Affiliated Hospital of Xian Jiaotong University, Xian 710004, China)

[Abstract] Objective To investigate the role of the spleen in the progression of hepatic carcinoma induced by chronic stress. Methods The murine H22 subcutaneous hepatoma model was established. Chronic restraint stress(CRS) model was used to explore the role of chronic stress in the progression of hepatic carcinoma. The proportion of CD11b+Ly6C+CCR2+ monocytes in peripheral blood and tumor tissue was detected by flow cytometry, and the role of the spleen in the progression of hepatic carcinoma induced by chronic stress was investigated by splenectomy. Results The tumor weight was significantly greater, and the proportion of CD11b+Ly6C+CCR2+ monocytes in peripheral blood were significantly increased in stress group, as compared with control group, suggesting significant differences(P<0.05). However, the proportion of CD11b+Ly6C+CCR2+ monocytes in tumor tissue of stress group did not change significantly compared with control group(P>0.05). The tumor weight and the proportion of CD11b+Ly6C+CCR2+ monocytes in peripheral blood in sham operation stress group were significantly higher than those in sham operation group and splenectomy stress group(P<0.01) while there were no significant differences in the tumor weight and the proportion of CD11b+Ly6C+CCR2+ monocytes in the peripheral blood between sham operation stress group and splenectomy stress group(P>0.05). The proportion of CD11b+Ly6C+CCR2+ monocytes in tumor tissue in sham operation stress group and splenectomy stress group did not change significantly compared with sham operation group(P>0.05). Conclusion Chronic stress could promote the progression of hepatic carcinoma and inhibit the activity of anti-tumor immunity. Splenectomy could slow down the progression of hepatic carcinoma induced by chronic stress possibly by reducing the proportion of CD11b+Ly6C+CCR2+ monocytes.

[Key words] liver neoplasms; spleen; chronic stress

[收稿日期]2020-08-21

[基金项目]国家自然科学基金项目(91842307); 陕西省自然科学基金项目(2021JQ-410);西安交通大学第二附属医院青年基金项目(YJ (QN) 2018.07)

[作者简介]江维(1990-),男,四川安岳人,西安交通大学第二附属医院助理研究员,医学博士,从事肿瘤免疫、神经内分泌免疫异常研究。

*通信作者。E-mail:lzf2568@xjtu.edu.cn

[中图分类号] R735.7

[文献标志码] A

[文章编号]1007-3205(2021)05-0520-05

(本文编辑:赵丽洁)